Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | PKM | P14618 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | GBA1 | P04062 | 1/20 | 0.50 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | PKLR | P30613 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3207580 | 0.81 | HSD11B1 (0.72) | LMNAHTTGBA1MAPTMEN1 | |
| SCHEMBL9093446 | 0.79 | TSHR (0.66) | ALDH1A1LMNAMAPTMEN1KMT2A | |
| SCHEMBL9094231 | 0.76 | GBA1 (0.51) | ALDH1A1LMNAPKMGBA1PKLR | |
| SCHEMBL8693767 | 0.73 | GBA1 (0.48) | ALDH1A1LMNAPKMGBA1PKLR | |
| SCHEMBL31315849 | 0.72 | PKM (0.70) | ALDH1A1LMNAPKMPKLRMEN1 | |
| SCHEMBL5249712 | 0.72 | LMNA (0.68) | ALDH1A1LMNAPKMHTTPTPN11 | |
| SCHEMBL20887238 | 0.71 | NPY5R (0.57) | ALDH1A1HPGDLMNAHTTSMN1; SMN2 | |
| SCHEMBL8692546 | 0.71 | GBA1 (0.46) | ALDH1A1LMNAPKMGBA1PKLR | |
| SCHEMBL1617636 | 0.70 | HDAC1 (0.76) | LMNAGBA1 | |
| SCHEMBL20887056 | 0.70 | HSD17B10 (0.55) | ALDH1A1HPGDPTPN11MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | XIANG JASON SHAOYUN | 2010-02-04 | — | — | US | disclosed |
| US-7632838-B2 | 11-beta HSD1 inhibitors | WYETH (US) | 2009-12-15 | — | — | US | disclosed |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | HSD11B1, HSD3B1, HSD11B2 | ALDH1A1 116/4885HPGD 79/4885LMNA 3748/4885 |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | HSD11B1, HSD11B2, HSD3B1 | ALDH1A1 123/4885HPGD 57/4885LMNA 3681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.